Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GSK’s pazopanib ‘shows promise across multiple areas’

GSK’s pazopanib ‘shows promise across multiple areas’

3rd June 2008

GlaxoSmithKline (GSK) has announced the publication of new data for its novel anti-cancer agent pazopanib which has shown promise over a number of cancers.

The two phase II studies showed the potential of the compound as a treatment for advanced renal cell cancer and early-stage non-small cell lung cancer.

Patients with advanced renal cell cancer showed an overall response rate of 35 per cent, with a median duration of response of longer than 16 months and median progression free survival of 11.9 months.

In patients with stage I-III non-small cell lung cancer, 86 per cent of those receiving pazopanib monotherapy saw a reduction in the volume of their tumours.

Thierry Le Chevalier, vice-president of the oncology medicine development centre at GSK, said: “These very promising results highlight the potential of pazopanib as a future treatment option across multiple forms of cancer.”

He added that the studies underline the companies continuing dedication to the development of novel and effective treatments in oncology.

Last month, GSK announced that it would enter into the global phase III study in partnership with the Breast International Group and Spanish Breast Cancer Cooperative Group to assess Tykerb/Tyverb (lapatinib) as a treatment for breast cancer in its early stages.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.